Drug Profile
ASF 1057
Alternative Names: ASF-1057; Monooctanoin/nicotinamide creamLatest Information Update: 22 Apr 2021
Price :
$50
*
At a glance
- Originator Astion Pharma A/S
- Class Nonsteroidal anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Seborrhoeic dermatitis
Most Recent Events
- 22 Apr 2021 ASF 1057 is still in phase III trials for Seborrhoeic dermatitis in France and Finland (Topical) (EudraCT2007-004649-14)
- 22 Apr 2021 Discontinued - Phase-III for Seborrhoeic dermatitis in Canada, Sweden, Denmark, United Kingdom (Topical)
- 01 Feb 2018 ASF 1057 is still in phase III trials for Seborrhoeic dermatitis in France and Finland (Topical) (EudraCT2007-004649-14)